Oppenheimer Upgrades Moderna (MRNA) to Outperform on visibility on COVID-19 vaccine sales, OPEX progression and 2024/25 catalysts
Tweet Send to a Friend
(Updated - January 2, 2024 6:57 AM EST)
Oppenheimer analyst Hartaj Singh upgraded Moderna (NASDAQ: MRNA) from Perform to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Hartaj Singh upgraded Moderna (NASDAQ: MRNA) from Perform to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
